

Clinical Pharmacology and Toxicology

The Residency Program in Clinical Pharmacology and Medical Toxicology is a two-year supervised training program open to qualified medical residents who have completed four or more years in Psychiatry, Anesthesia, Emergency Medicine, or three years or more in Core Internal Medicine or Pediatrics.

The objective of this program is to provide research training in clinical pharmacology and medical toxicology to residents interested in specific aspects of these disciplines.

This University integrated residency program initiated in 1989, is accredited by the Royal College of Physicians and Surgeons of Canada and leads to a specialty certificate in Clinical Pharmacology and Toxicology from the Royal College of Physicians and Surgeons of Canada upon completion of the second year and completion of a written examination. This residency program is based in the Clinical Psychopharmacology and Therapeutics Unit of the McGill University Health Centre (MUHC), Department of Psychiatry, McGill University, and is carried out in collaboration with a number of University hospitals and centers, namely the Clinical Toxicology Consult Service of the MUHC, Internal Medicine at the MUHC (Hypertension clinic), the Jewish General Hospital, Douglas Mental Health University Institute, and the Montreal Neurological Hospital and Institute; as well as the Department of Pharmacy of the MUHC, and the Department of Epidemiology and Biostatistics of McGill University.

The mandatory content of the first year consists of:

- 1) 6-7, 4 week periods spent in one of the core specialty units of the program such as the Clinical Psychopharmacology and Therapeutics Unit concentrating on psychopharmacological consultations, or the Toxicology Unit focusing on clinical pharmacology of toxicology consultations or Anesthesia pharmacotherapy.
- 2) The trainee then selects one or two rotation(s) 2-4 periods in length each in clinical neuropsychopharmacology and neuropsychiatry; anesthesia; toxicology (emergency medicine) or psychopharmacology (the latter 3 if not completed as their core specialty).
- 3) The last 2-4 periods are completed in geriatrics (neurological) and internal medicine, focusing on clinical pharmacology in areas that are important to develop a rounded education of the majority of pharmacotherapeutics (dementia, Parkinson's disease, HTA).

The elective content of the second year is flexible and tailored to the specific individual interests of the resident trainee.

The following rotations are available:

- clinical pharmacology research in psychiatry or anesthesia;
- clinical toxicology research;

- clinical exploratory pharmacology research in psychiatry, anesthesia or toxicology;
- pre-clinical pharmacology research;
- statistics and epidemiology;
- and pharmaceutical sciences.
- Other research electives may be arranged depending on the resident's career goals and interests.

Clinical Pharmacology and Toxicology and Psychopharmacology Seminars, in addition to regular teaching rounds, are given in cooperation with regular and visiting lecturers throughout the training period.

Admission is based on:

- 1) a resident's record,
- 2) autobiographical letter
- 3) curriculum vitae,
- 4) reference letters (2-3) assessment,
- 5) interviews with the Selection Committee (Program Director and 1-3 Program Committee Members) which are structured to examine professional and personal qualifications for clinical pharmacology.

An MD degree (or equivalent) is required to apply and residents of foreign countries should contact the Faculty of Medicine first in order to determine if they indeed qualify to apply for this residency program.

Enquiries should be made in advance of the anticipated date of entry to the program in order to arrange rotations congruent with the trainee's future career plans.

Requests for further information should be directed to:

Dr Howard Margolese
Director, Residency Program in Clinical Pharmacology and Toxicology
Clinical Psychopharmacology and Therapeutics Unit
McGill University Health Centre
1025 Pine Avenue West
Montreal, Quebec H3A 1A1
Tel.: (514) 398-2958
Fax: (514) 843-2898
E-mail: clinicalpharm.psychiatry@mcgill.ca

OR

Dr. Sophie Gosselin

Assistant Director, Residency Program in Clinical Pharmacology and Toxicology

Director, Clinical Toxicology Consult Service - MUHC RVH and MGH sites.

McGill University Health Centre

687 Pine Ave West

Montreal, Quebec H3A 1A1

Tel: (514) 934-1934 x 34277

sophie.gosselin@mcgill.ca

revJan2012